ここ数十年で、がん治療は既存の治療法の治療効果を改善することを目的とした多くの新しいアプローチがありました。化学療法や放射線療法などの標準治療は、大きな進歩にもかかわらず、多くのがん患者に対して長期的な寛解や治癒を達成できないことがよくあります。その結果、研究者は新しい治療法に着目し、その1つが免疫学的チェックポイントタンパク質LAG-3(リンパ球活性化遺伝子-3)を標的としています。現在、いくつかのLAG-3阻害剤が臨床試験中であり、市販されているのは1つだけですが、LAG-3阻害剤市場は、世界的ながん症例の増加と製薬会社や研究者によるこの新興医薬品クラスへの関心の高まりにより、今後数年間で前例のない速度で成長すると予想されます。
目次
Table of Content
1. Introduction to LAG-3 Inhibitor
1.1 Overview Of LAG-3 inhibitor
1.2 Mechanism of Action
1.3 LAG-3 Targeted Therapy Approaches
2. Global LAG-3 Inhibitor Clinical Trials Overview
2.1 By Phase
2.2 By Country
2.3 By Company
2.4 By Indication
2.5 By Priority Status
2.6 Patient Segment
3. Global LAG-3 Inhibitors Market Scenario
3.1 Current Market Outlook (2022 Till Q1’2024)
3.2 Future Market Outlook (2024 - 2029)
4. LAG-3 Inhibitor Market Regional Analysis
4.1 South Korea
4.2 Australia
4.3 Canada
4.4 Japan
4.5 UK
4.6 Europe
4.7 China
4.8 US
5. LAG-3 Inhibitor Market Development By Indications
5.1 Lymphoma
5.2 Melanoma
5.3 Lung Cancer
5.4 Colorectal Cancer
5.5 Head and Neck Cancer
5.6 Esophageal Cancer
6. Opdualag (Nivolumab and Relatlimab-rmbw) - Overview, Pricing, Dosing and Sales Analysis
6.1 Overview
6.2 Pricing and Dosing
6.3 Sales (2022 Till Q1’2024)
7. Combination Stratagems for LAG-3 Inhibitors
8. Global LAG-3 Inhibitors clinical Trials Insight By Company, Country, Indication and Phase
8.1 Research
8.2 Preclinical
8.3 Phase I
8.4 Phase I/II
8.5 Phase II
8.6 Phase II/III
8.7 Phase III
9. Marketed LAG-3 Inhibitor Clinical insight
10. Global LAG-3 Inhibitors Market Dynamics
10.1 Market Drivers
10.2 Market Challenges
11. Competitive Landscape
11.1 Abeome Corporation
11.2 ABL Bio
11.3 Agenus
11.4 Akeso Biopharma
11.5 AnaptysBio
11.6 Bristol-Myers Squibb
11.7 EpimAb Biotherapeutics
11.8 F-star Therapeutics
11.9 Immutep
11.10 Incyte Corporation
11.11 Innovent Biologics
11.12 Merck
11.13 Roche
11.14 Shanghai Fosun Pharmaceutical
11.15 Y-Biologics
List of Figures
Figure 1-1: LAG-3/MHC Class II Signaling Pathway
Figure 12: LAG-3 Inhibitor - Mechanism of Action
Figure 1-3: Binding Efficacy of Bispecific Antibodies
Figure 2-1: Global - LAG-3 Inhibitor Clinical Trials By Phase (Numbers), 2024 - 2029
Figure 2-2: Global - LAG-3 Inhibitor Clinical Trials By Country (Numbers), 2024 - 2029
Figure 2-3: Global - LAG-3 Inhibitor Clinical Trials By Company (Numbers), 2024 - 2029
Figure 2-4: Global - LAG-3 Inhibitor Clinical Trials By Indication (Numbers), 2024 - 2029
Figure 2-5: Global - LAG-3 Inhibitor Clinical Trials By Priority Status (Numbers), 2024 - 2029
Figure 2-6: Global - LAG-3 Inhibitor Clinical Trials By Patient Segment (Numbers), 2024 - 2029
Figure 3-1: Global - LAG 3 Inhibitor Market (US$ Million), 2022 and 2023
Figure 3-2: Global - LAG 3 Inhibitor Market By Region(US$ Million), 2023
Figure 3-3:Global - LAG 3 Inhibitor Market By Region (%), 2023
Figure 3-4: Global - LAG 3 Inhibitor Market By Region (US$ Million), Q1’2024
Figure 3-5: Combination of Anti-LAG-3 Antibody with a Virus-Like Drug Conjugate (VDC), AU-011
Figure 3-6: Aspects Determining LAG-3 Inhibitor Future
Figure 3-7: Global - LAG 3 Inhibitor Market Forecast (US$ Million), 2024 - 2029
Figure 4-1 ABL501 Phase I (NCT05101109) Study - Initiation and Completion Year
Figure 4-2: Y Biologics Preclinical LAG-3 Candidate
Figure 4-3 NCT06259162 Study - Initiation and Completion Year
Figure 4-4 LBL-007 Phase I/II (NCT03744468) Study - Initiation and Completion Year
Figure 4-5 Relatlimab and Nivolumab Phase II (NCT05418972) Study - Initiation and Completion Year
Figure 4-6 Eftilagimod Alpha (IMP321) With Pembrolizumab Phase II (NCT03625323) Study - Initiation and Completion Year
Figure 4-7 Fianlimab and Cemiplimab Phase III (NCT05352672) Study - Initiation and Completion Year
Figure 4-8: Canada- Features Prompting LAG-3 Inhibitor Market
Figure 4-9: Relatlimab With or Without Nivolumab Phase I (NCT02966548) Study - Initiation and Completion Year
Figure 4-10: Relatlimab - Ongoing Studies Indication and Location Insights
Figure 4-11: Margetuximab in Combination With INCMGA00012 and Chemotherapy Phase II/III (NCT04082364) Study - Initiation and Completion Year
Figure 4-12: FS118 Phase I/II (NCT03440437) Study - Initiation and Completion Year
Figure 4-13: Europe Research Institutes and Hospitals Conducting LAG-3 Inhibitor Clinical Trials
Figure 4-14: INCAGN02385 and INCAGN02390 Phase II (NCT05287113) Study - Initiation and Completion Year
Figure 4-15: IMP321 with Immunotherapeutic/Targeted/Chemotherapeutic Agents Phase I (NCT03252938) Study - Initiation and Completion Year
Figure 4-16: Sym021 With Sym022 or Sym023 Phase I (NCT04641871) Study - Initiation and Completion Year
Figure 4-17: Tobemstomig with Atezolizumab, Bevacizumab and Tiragolumab Phase I/II (NCT05908786) Study - Initiation and Completion Year
Figure 4-18: AK129 Phase 1 (NCT05645276) Study - Initiation and Completion Year
Figure 4-19: LBL-007 Phase 1 (NCT04640545) Study - Initiation and Completion Year
Figure 5-1: Opdualag Phase 1/2 (NCT05255601) Study - Initiation and Completion Year
Figure 5-2: INCAGN02385 Phase 1 (NCT06290622) Study - Initiation and Completion Year
Figure 5-3: Favezelimab Phase 1/2 (NCT03598608) Study - Initiation and Completion Year
Figure 5-4: Fianlimab Phase 3 (NCT05352672) Study - Initiation and Completion Year
Figure 5-5: Fianlimab Phase 3 (NCT05608291) Study - Initiation and Completion Year
Figure 5-6: INCAGN02385 Phase 1/2 (NCT04370704) Study - Initiation and Completion Year
Figure 5-7: XmAb22841 Phase 1 (NCT05695898) Study - Initiation and Completion Year
Figure 5-8: Fianlimab Phase 2/3 (NCT05785767) Study - Initiation and Completion Year
Figure 5-9: Fianlimab Phase 2/3 (NCT05800015) Study - Initiation and Completion Year
Figure 5-10: Fianlimab Phase 2 (NCT03916627) Study - Initiation and Completion Year
Figure 5-11: Fianlimab Phase 2 (NCT06161441) Study - Initiation and Completion Year
Figure 5-12: HLX26 Phase 2 (NCT05787613) Study - Initiation and Completion Year
Figure 5-13: Favezelimab Phase 3 (NCT05064059) Study - Initiation and Completion Year
Figure 5-14: Fianlimab Phase 2 (NCT06205836) Study - Initiation and Completion Year
Figure 5-15: Relatlimab Phase 2 (NCT03642067) Study - Initiation and Completion Year
Figure 5-16: Relatlimab Phase 2 (NCT04080804) Study - Initiation and Completion Year
Figure 5-17: FS118 Phase 1/2 (NCT03440437) Study - Initiation and Completion Year
Figure 5-18: Tobemstomig Phase 1/2 (NCT04140500) Study - Initiation and Completion Year
Figure 5-19: Tobemstomig Phase 2 (NCT04785820) Study - Initiation and Completion Year
Figure 5-20: Relatlimab Phase 1 (NCT03044613) Study - Initiation and Completion Year
Figure 6-1: Opdualag - Approval Year by Region
Figure 6-2: Opdualag - Estimated Minimum Market Exclusivity Date, 2024
Figure 6-3: US - Cost per Unit and Supply of Opdualag (US$), June’2024
Figure 6-4: EU - Cost per Unit and Supply of Opdualag (US$), June’2024
Figure 6-5: Global - Opdualag Annual Sales (US$ Million), 2022-2023
Figure 6-6: Global - Opdualag Sales by Region (US$ Million), 2023
Figure 6-7: Global - Opdualag Annual Sales by Region (%), 2023
Figure 6-8: Global - Opdualag Quarterly Sales (US$ Million), Q1’2024
Figure 6-9: Global - Opdualag Quarterly Sales (US$ Million), Q1-Q4’2023
Figure 6-10: US - Opdualag Quarterly Sales (US$ Million), 2023
Figure 6-11: ROW - Opdualag Quarterly Sales (US$ Million), 2023
Figure 7-1: Overview to LAG-3 Combinations
Figure 10-1: LAG-3 Inhibitor - Market Drivers
Figure 10-2: LAG-3 Inhibitor - Market Challenges
List of Tables
Table 3-1: China - Ongoing Clinical Trials for LAG-3 Inhibitors
Table 3-2: US - Some Ongoing Clinical Trials for LAG-3 Inhibitors
Table 4-1: Lymphoma - Some Ongoing Clinical Trials for LAG-3 Inhibitors
Table 4-2: Melanoma - Some Ongoing Clinical Trials for LAG-3 Inhibitors
Table 5-1: Opdualag - Maximum Infusion Volumes and Concentration Ranges by Patient Group
Table 5-2: Opdualag - Recommended Dosage Modifications for Adverse Reactions
Table 6-1: Ongoing Preclinical and Clinical trials for Combination of LAG-3 inhibitors
Table 8-1: Agenus - Financials and CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 8-2: AnaptysBio - Financials and CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 8-3: Bristol-Myers Squibb - Financials and CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 8-4: F-star - Financials and CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 8-5: Immutep - Financials and CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 8-6: Incyte Corporation - Financials and CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 8-7: Innovent Biologics - Financials and CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 8-9: Merck KGaA - Financials and CD223 Antigen Inhibitors Drugs Clinical Trials Insight
Table 8-10: Shanghai Fosun Pharmaceutical - Financials and CD223 Antigen Inhibitors Drugs Clinical Trials Insight
